Literature DB >> 8731706

Pulmonary embolism--the role of thrombolytic therapy in its management.

R S More1, A Chauhan.   

Abstract

In massive pulmonary embolism where there may be evidence of right ventricular dysfunction and acute pulmonary hypertension, anticoagulation therapy alone may prove inadequate. In such situations use of thrombolytic agents produces an improvement in haemodynamics compared to anticoagulants alone, although studies to date have been too small to address the issue of mortality benefit. It would appear that all age groups gain benefit from the use of thrombolytics. Studies that have compared thrombolytic agents and anticoagulants are discussed. In addition, the issues of the choice of thrombolytic agent and the different modes of delivery of therapy are addressed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8731706      PMCID: PMC2398394          DOI: 10.1136/pgmj.72.845.157

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  43 in total

1.  Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators.

Authors: 
Journal:  Chest       Date:  1990-03       Impact factor: 9.410

2.  Selection of patients with pulmonary embolism for thrombolytic therapy.

Authors:  V V Kakkar; E B Raftery
Journal:  Lancet       Date:  1970-08-01       Impact factor: 79.321

3.  Resolution rate of acute pulmonary embolism in man.

Authors:  J E Dalen; J S Banas; H L Brooks; G L Evans; J A Paraskos; L Dexter
Journal:  N Engl J Med       Date:  1969-05-29       Impact factor: 91.245

4.  Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism.

Authors:  G A Miller; G C Sutton; I H Kerr; R V Gibson; M Honey
Journal:  Br Med J       Date:  1971-06-19

5.  Urokinase versus tissue plasminogen activator in pulmonary embolism.

Authors: 
Journal:  Lancet       Date:  1988-09-17       Impact factor: 79.321

6.  Recovery of pulmonary arterial blood flow in patients with pulmonary embolism.

Authors:  D E Tow; H N Wagner
Journal:  N Engl J Med       Date:  1967-05-11       Impact factor: 91.245

7.  A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.

Authors:  M Levine; J Hirsh; J Weitz; M Cruickshank; J Neemeh; A G Turpie; M Gent
Journal:  Chest       Date:  1990-12       Impact factor: 9.410

8.  Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion.

Authors:  S Z Goldhaber; W D Haire; M L Feldstein; M Miller; R Toltzis; J L Smith; A M Taveira da Silva; P C Come; R T Lee; J A Parker
Journal:  Lancet       Date:  1993-02-27       Impact factor: 79.321

9.  Streptokinase therapy in acute major pulmonary embolism: effectiveness and problems.

Authors:  J Hirsh; G S Hale; I G McDonald; R A McCarthy; A Pitt
Journal:  Br Med J       Date:  1968-12-21

10.  Comparison of the effects of streptokinase and heparin on the early rate of resolution of major pulmonary embolism.

Authors:  J Hirsh; I G McDonald; G A Hale; E F O'Sullivan; V M Jelinek
Journal:  Can Med Assoc J       Date:  1971-03-20       Impact factor: 8.262

View more
  3 in total

1.  Low-molecular-weight heparin for treatment of submassive pulmonary embolism after pneumonectomy.

Authors:  Dalokay Kilic; Sule Akin; Alper Findikcioglu; Ahmet Bilen; Anis Aribogan; Ahmet Hatipoglu
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-07

2.  An unusual presentation of massive pulmonary embolism mimicking septal acute myocardial infarction treated with tenecteplase.

Authors:  Sergio Fasullo; Salvatore Paterna; Pietro Di Pasquale
Journal:  J Thromb Thrombolysis       Date:  2008-01-09       Impact factor: 2.300

Review 3.  Applications of thrombolytic therapy.

Authors:  N Curzen; R Haque; A Timmis
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 41.787

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.